Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (June 2008)

46 slides from Auxilium Pharmaceuticals's investor presentation, Jun 25, 2008

  1. Slide 1: June 2008

    Exhibit 99.1 June 2008

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma

  3. Slide 3: Fastest Growing TRT Product, Late Stage Blockbuster Opportunity

    Fastest Growing TRT product in the U.S. Late Stage Blockbuster Product Opportunity Poised for Growth + =

  4. Slide 4: Auxilium Pharmaceuticals, Inc.

    Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 32

  5. Slide 5: Broad Maturing Pipeline

    Broad Maturing Pipeline Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Phase III Market Phase II Phase I Broad Maturing Pipeline Note: Worldwide rights for all products available, except Testim where ex -U.S. rights have been licensed. XIAFLEX™ (c

  6. Slide 6: Anticipated News Flow Events

    Anticipated News Flow Events Q409 Q309 Q209 Q109 2010 Anticipated News Flow Events Q308: • XIAFLEX- Initiate Peyronie's Phase IIb Study H109: • XIAFLEX- Open Label Safety Data Early 2009: • XIAFLEX- File BLA for Dupuytren's Contracture Early 2010 • XIAFLEX – FDA Approval In Dupuytren’s Contracture Q

  7. Slide 7: XIAFLEX (clostridial collagenase for injection)

    XIAFLEX™ (clostridial collagenase for injection) Unique, Late-Stage Opportunity with Blockbuster Potential

  8. Slide 8: XIAFLEX - Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity • Potential to be first effective non-surgical treatment for two high unmet needs – Late-Stage Phase III data for the treatment of Dupuytren’s contracture -expect to file U.S. BLA in early 2009

  9. Slide 9: Dupuytren's Contracture—a Debilitating Condition

    Dupuytren’s Contracture—a Debilitating Condition Dupuytren’s Contracture—a Debilitating Condition • Excessive collagen deposition • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Debilitating effect on quality of life • Surgery may be reser

  10. Slide 10: Current Treatment Options Are Invasive or Ineffective

    Current Treatment Options Are Invasive or Ineffective Current Treatment Options Are Invasive or Ineffective • Surgery • Non-surgical options – Splinting – Physical therapy – Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation

  11. Slide 11: Dupuytren's Contracture—Unmet Medical Need

    Dupuytren’s Contracture—Unmet Medical Need Dupuytren’s Contracture—Unmet Medical Need • Disease prevalence is estimated at 3%-6% among adult Caucasians, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients

  12. Slide 12: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture

    XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture

  13. Slide 13: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture

    XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture

  14. Slide 14: Pivotal Phase III Study (DUPY-303): Results

    Pivotal Phase III Study (DUPY-303): Results* 0/12 0/7 0/5 91% 86% 100% 85% 0% 0% 0% 0% 20% 40% 60% 80% 100% Pivotal Phase III Study (DUPY-303): Results* • 54/62 (87%) joints achieved 0°-5° contracture in the study and its open-label extension • Recurrence rates – 3 of 54 joints followed for 12 month

  15. Slide 15: Most Patients Achieved Full Extension, Regardless of Joint or Severity

    Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity 92% 78% 86% 61% 47% 53% 79% 60% 70% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% MP PIP Combined 10,000 units, approximately 0.58 mg. Joint T

  16. Slide 16: CORD I Design

    CORD I Design CORD I Design • Largest ever double-blind, placebo-controlled trial in Dupuytren’s Contracture – randomized in 2:1 ratio of active to placebo – enrolled a 2:1 ratio of MP:PIP – enrolled 1:1 ratio of less severe to more severe joints • Primary endpoint is reduction in contracture to wit

  17. Slide 17: Primary Endpoint Outcome Compares Favorably To Surgery

    Primary Endpoint Outcome Compares Favorably To Surgery Primary Endpoint Outcome Compares Favorably To Surgery

  18. Slide 18: 4 Out Of 5 Dupuytren's Patients Improved By 50%

    4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50% 4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50%

  19. Slide 19: Contracture Reduction By Degrees Indicates Average Patient Achieves ~10°

    Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture

  20. Slide 20: XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications

    XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Serious Adverse Events Number Rate/Inj. Tendon / Ligament: Confirmed Tendon Rupture 0.14% Unconfirmed Tendon Rupture 0.05% Ligam

  21. Slide 21: CORD I Key Takeaways

    CORD I Key Takeaways CORD I Key Takeaways • Primary endpoint of 5° reached in 64% of patients (p<0.001) – 25 of 26 endpoints met with statistical significance of <0.001, 1 of 26 was met with a p-value = 0.002 – Of the 73 patients who didn’t respond, 44 received less than 3 injections and 25 had no p

  22. Slide 22: Dupuytren's Commercial Opportunity

    Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; about half have contractures in both hands • Early data indicates on averag

  23. Slide 23: Market Research Performed – Dupuytren's

    Market Research Performed – Dupuytren’s Market Research Performed – Dupuytren’s • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571

  24. Slide 24: At least 240,000 Dupuytren's Candidates In U.S. & Europe Annually

    At least 240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 X

  25. Slide 25: Expected Pathway to BLA Filing in Early 2009

    Expected Pathway to BLA Filing in Early 2009 Expected Pathway to BLA Filing in Early 2009 • Complete 12 month open-label safety follow up from >100 CORD I patients originally randomized to XIAFLEX • Complete open-label CORD II and JOINT I/II trials to attain 1,000 patient exposure data • Finalize BL

  26. Slide 26: XIAFLEX I.P. Position for Dupuytren's Contracture

    XIAFLEX I.P. Position for Dupuytren’s Contracture XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug Exclusivity granted on May 23, 1996 for 7 years post approval • Market Exclusivity expected in EU for 10 years post - approval –Data protection granted for 8 years • Method of Use P

  27. Slide 27: Peyronie's Disease—a Devastating Disorder

    Peyronie’s Disease—a Devastating Disorder 1. Smith BH. Am J Clin Pathol . 1966;45:670-678. 2. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Peyronie’s Disease—a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Sympt

  28. Slide 28: Epidemiology—Peyronie's Disease

    Epidemiology—Peyronie’s Disease Epidemiology—Peyronie’s Disease • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men – Actual prevalence higher based on autopsies • Prevalence rate increases with age – The average age of disease onset is 53 years • High association with other disease

  29. Slide 29: Current Treatment—Surgical

    Current Treatment—Surgical Current Treatment—Surgical • The goal of surgery is simply to make the two sides of the penis equal in size • Graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K

  30. Slide 30: Peyronie's Disease—Unapproved Treatments Have Been Used With Little Success

    Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Ener

  31. Slide 31: Promising Phase II Results: 25% Reduction in Angle of Deviation

    Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Study 1030 58% 53% 35% 0% 20% 40% 60% 80% 100% Month 3 Month 6 Month 9 Study 1035 50% 100% 100% 89% 0% 20% 40% 60% 80% 100% Week 6 Month

  32. Slide 32: Market Research Performed – Peyronie's

    Market Research Performed – Peyronie’s Market Research Performed – Peyronie’s • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and

  33. Slide 33: At least 210,000 Peyronie's Candidates In U.S. and Europe Annually

    At least 210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates or 67% of Medical/ Surgical candidates

  34. Slide 34: Peyronie's Clinical Plan

    Peyronie’s Clinical Plan Peyronie’s Clinical Plan • Phase IIb dose ranging study expected to begin in Q3 2008 • A proprietary Patient Reported Outcome (PRO) questionnaire has been developed – To be validated in Phase IIb and likely to be used as a primary efficacy endpoint in Phase III clinical tria

  35. Slide 35: XIAFLEX I.P. Position for Peyronie's Disease

    XIAFLEX I.P. Position for Peyronie’s Disease XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug Exclusivity granted on March 12, 1996 for 7 years post approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication –Biosimilars would need to genera

  36. Slide 36: Testim 1% Testosterone Gel: Near-Term Growth Driver

    Testim ® 1% Testosterone Gel: Near-Term Growth Driver Executing on Opportunities

  37. Slide 37: Testim is the Fastest Growing Testosterone Replacement Therapy Gel

    Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45

  38. Slide 38: 447% +30%

    447% +30%

  39. Slide 39: Gels Fastest Growing TRT Segment

    Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Apr 2008 L12M: 23.6+% Gel Segment Growth ($) Gel Segment Growth ($) Ap

  40. Slide 40: Established Track Record of Consistent Growth

    Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth $- $5 $10 $15 $20 $25 $30 Net Revs TRX ® ($ in millions) Established Track Record of Consistent Growth Q1 2008 Net Revenues Y/Y Growth: +47.2% Q1 2008 Net Q1 2008 Net Revenues Revenues Y/Y Growth: Y/Y Growth: +

  41. Slide 41: Testim Share of TRx of Gel Market

    We Believe Testim Is Driving Growth in Overall Gel Market Testim Share of TRx of Gel Market Source: IMS data 21.9% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% Mar-03 May-08 Strong market share with high-prescribing urologists & PCP’s; 41.3% gel market share of decile 8-10 Urologists and 28.8% share with decil

  42. Slide 42: Testim Patent Coverage

    Testim Patent Coverage • U.S. Patent # 7,320,968 covering method of use claims for Testim issued January 22, 2008; expires 2025 • We believe no Paragraph III ANDA was filed prior to issuance of the ’968 patent, since five months have passed since listing in the Orange Book • Divisional application a

  43. Slide 43: Financials / Strategic Priorities

    Financials / Strategic Priorities

  44. Slide 44: 1Q08 Financial Results and 2008 Guidance

    1Q08 Financial Results and 2008 Guidance ($ Millions) Q1 ’07 Q1 ’08 Guidance Revenues $18.4 $27.1 $120-125 R&D Expense $8.7 $13.2 $52-56 SG&A Expense $17.2 $21.0 $88-92 Net Loss ($11.9) ($12.3) ($44-48) Stock – Based Comp Expense $1.2 $2.1 $9-11 Cash & cash equivalents $56.9 1Q08 Financial Results a

  45. Slide 45: Strategic Priorities

    Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – File Dupuytren’s BLA in early 2009 – Initiate Phase IIb in Peyronie’s Disease in Q3 2008 – Continue market research activities; prepare commercial team – Continue development of XIAFLEX in Peyronie’s Diseas

  46. Slide 46: Fastest Growing TRT Product, Late Stage Blockbuster Opportunity

    Fastest Growing TRT product in the U.S. Late Stage Blockbuster Product Opportunity Poised for Growth + =

Auxilium Pharmaceuticals — Investor Presentation (June 2008) on 6ix